Clinical Trials: Country-Specific Clinical Trials

Emerging Role of Decentralized Trials in India: Regulatory Landscape and Implementation Insights

Posted on digi By digi

Decentralized clinical trials offer immense potential for transforming India’s clinical research ecosystem by improving accessibility, patient-centricity, and trial efficiency. While the regulatory framework continues to evolve, proactive engagement with Ethics Committees, adherence to GCP standards, and strategic investment in digital tools can ensure successful implementation of DCTs in India. Sponsors who embrace this shift today will be better positioned for the future of global clinical research.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Case Study: First-in-Human Trials Conducted in China

Posted on digi By digi

Sponsors should engage the NMPA early through pre-IND consultations, select accredited Phase I units with strong safety infrastructure, and implement robust pharmacovigilance systems. CRO partnerships are essential for operational support, particularly in site readiness and data management. Early patient advocacy engagement improves recruitment and trust in high-risk early-phase studies.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

EU Pediatric Clinical Trial Case Studies

Posted on digi By digi

Pediatric trials require tailored considerations:

Oncology: Multi-country collaboration is essential to achieve sufficient enrollment.
Rare Diseases: Registries and patient advocacy groups are critical for recruitment.
Vaccines: Ethical justification for pediatric enrollment must weigh risks and public health benefits.
Decentralized Trials: Digital tools such as eConsent and remote monitoring may improve access but must comply with GDPR.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Clinical Data Protection Under Indian IT Act and DPDP Act: What Sponsors and Investigators Must Know

Posted on digi By digi

India’s data protection landscape is evolving rapidly, and clinical trial stakeholders must align their operations with both regulatory and ethical expectations. By harmonizing Good Clinical Practice (GCP) with the provisions of the IT Act and the DPDP Act, sponsors and CROs can safeguard patient confidentiality, ensure trial compliance, and avoid significant legal and reputational risks. Proactive planning, staff training, and robust documentation are essential to stay ahead of India’s maturing data protection enforcement regime.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Post-Market Safety Surveillance in China

Posted on digi By digi

Sponsors should implement robust PV systems with validated databases, clear SOPs, and trained safety staff. Collaborating with CROs ensures compliance with reporting timelines and active monitoring. Establishing risk communication channels with patients and healthcare providers improves reporting quality. Regular mock inspections help organizations prepare for NMPA audits.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

CRO Partnerships in Post-Brexit UK Clinical Research

Posted on digi By digi

CRO partnerships are a cornerstone of post-Brexit UK clinical research. By providing operational expertise, digital solutions, and regulatory support, CROs help sponsors navigate evolving MHRA frameworks and deliver trials efficiently. Strong sponsor oversight, transparent contracts, and alignment with global standards are critical for successful CRO collaborations. As clinical research becomes more decentralised and complex, CRO partnerships will continue to shape the resilience and competitiveness of the UK’s clinical trial ecosystem.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Top CRO Market Leaders in Indian Clinical Research and Their Regulatory Performance

Posted on digi By digi

India’s CRO ecosystem has matured into a high-quality, cost-effective engine powering global clinical development. From early-phase bioequivalence to late-phase trials and real-world evidence generation, top Indian CROs offer reliable infrastructure, regulatory know-how, and scientific depth. Sponsors looking to leverage India’s patient pool and trial-friendly regulations can find robust support among the country’s leading CROs—provided due diligence and strong oversight structures are in place.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Phase 4 and Post-Marketing Commitments in the EU

Posted on digi By digi

Phase 4 studies vary across therapeutic areas:

Oncology: Long-term monitoring for late toxicities is critical.
Pediatrics: Post-marketing commitments often address unmet needs in child populations.
Rare Diseases: Registries and global collaborations are essential for gathering meaningful post-marketing data.
Vaccines: Large-scale safety studies are often required to detect rare adverse events post-licensure.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials